Holen Sie sich die Stockscreener-App
0.1374
4.52%
-0.0065
Handel nachbörslich:
.14
0.0026
+1.89%
Schlusskurs vom Vortag:
$0.1439
Offen:
$0.1439
24-Stunden-Volumen:
1.96M
Relative Volume:
0.37
Marktkapitalisierung:
$3.94M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-8.74M
KGV:
-0.067
EPS:
-2.05
Netto-Cashflow:
$-8.25M
1W Leistung:
+2.84%
1M Leistung:
-25.49%
6M Leistung:
-97.35%
1J Leistung:
-99.70%
1-Tages-Spanne:
$0.1351
$0.1459
1-Wochen-Bereich:
$0.1231
$0.1693
52-Wochen-Spanne:
$0.1231
$62.60
Glucotrack Inc Stock (GCTK) Company Profile
Firmenname
Glucotrack Inc
Sektor
Telefon
972 (8) 675-7878
Adresse
301 RT 17 NORTH, RUTHERFORD
Vergleichen Sie GCTK mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GCTK
Glucotrack Inc
|
0.1374 | 3.83M | 0 | -8.74M | -8.25M | -2.05 |
|
ISRG
Intuitive Surgical Inc
|
558.06 | 199.19B | 8.71B | 2.48B | 1.75B | 6.82 |
|
BDX
Becton Dickinson Co
|
171.03 | 49.82B | 20.87B | 1.50B | 2.59B | 5.24 |
|
ALC
Alcon Inc
|
86.93 | 42.71B | 9.93B | 1.12B | 1.58B | 2.25 |
|
RMD
Resmed Inc
|
249.69 | 35.94B | 5.02B | 1.31B | 1.56B | 8.91 |
|
WST
West Pharmaceutical Services Inc
|
218.58 | 15.12B | 2.90B | 467.20M | 306.90M | 6.37 |
Glucotrack Inc Aktie (GCTK) Neueste Nachrichten
Glucotrack to Showcase Long-Term Continuous Blood Glucose Monitor at American Diabetes Association’s 85th Scientific Sessions - mx.advfn.com
GlucoTrack to Present at ADA Scientific Sessions - TipRanks
Revolutionary Diabetes Tech: Glucotrack's 3-Year Implantable Monitor Eliminates Daily Finger Pricks - Stock Titan
GCTK stock plunges to 52-week low, hits $0.13 By Investing.com - Investing.com South Africa
GCTK stock plunges to 52-week low, hits $0.13 - Investing.com Australia
Upcoming Benzinga Webinar With Glucotrack To Discuss The Potential Of Its Innovative CBGM Technology To Transform Diabetes Care And Patient Lives - The Globe and Mail
Glucotrack appoints new board member with diabetes tech expertise By Investing.com - Investing.com South Africa
Glucotrack appoints new board member with diabetes tech expertise - Investing.com
Glucotrack Strengthens Board of Directors with Election of Victoria E. Carr-Brendel, PhD - The Manila Times
GlucoTrack (NASDAQ:GCTK) Trading Down 0.2% – Time to Sell? - Defense World
GlucoTrack Approves Key Proposals at Annual Meeting - TipRanks
GCTK stock plunges to 52-week low, touches $0.13 - Investing.com Australia
GCTK stock plunges to 52-week low, touches $0.13 By Investing.com - Investing.com Nigeria
GlucoTrack Establishes Patient Advisory Board for CBGM - TipRanks
Glucotrack Establishes Patient Advisory Board to Inform Diabetes Technology Development - The Manila Times
Glucotrack, Inc. Forms Patient Advisory Board to Enhance Development of Continuous Blood Glucose Monitor - Nasdaq
Groundbreaking 3-Year Implantable Glucose Monitor Gets Patient-Led Development at Glucotrack - Stock Titan
Glucotrack Reports Q1 2025 Financial Results and Progress - TipRanks
Glucotrack Reports First Quarter 2025 Financial Results and Recent Corporate Highlights - The Manila Times
Innovative Continuous Blood Glucose Monitor Shows Promise in First Human Trial - citybuzz -
GlucoTrack Reports Q1 2025 Financial Results and Progress - TipRanks
Glucotrack, Inc. SEC 10-Q Report - TradingView
Glucotrack, Inc. Advances Continuous Blood Glucose Monitoring Technology with Clinical Study Initiation in Australia by Q3 2025 - Nasdaq
Glucotrack Reports First Quarter 2025 Financial Results And Recent Corporate Highlights - marketscreener.com
Breakthrough: Glucotrack's Implantable Diabetes Monitor Hits Clinical Milestone, FDA Decision Expected Q4 - Stock Titan
Glucotrack gains HREC approval for clinical study of CBGM device - Yahoo Finance
First-In-Human Study In The Bag, Glucotrack Gears Up For Long-Term Trial Of Potentially Groundbreaking Continuous Blood Glucose Monitor For Diabetes Patients - FinancialContent
Certain Options of GlucoTrack, Inc. are subject to a Lock-Up Agreement Ending on 14-MAY-2025. - marketscreener.com
Certain Common Stock of GlucoTrack, Inc. are subject to a Lock-Up Agreement Ending on 14-MAY-2025. - marketscreener.com
GlucoTrack Gains Approval for Long-Term Clinical Study - TipRanks
Glucotrack Announces Ethical Approval for Long-Term Clinical Study of Continuous Blood Glucose Monitor - The Manila Times
Geode Capital Management LLC Increases Stock Holdings in GlucoTrack, Inc. (NASDAQ:GCTK) - Defense World
GlucoTrack Inc (GCTK) can make a big difference with a little luck - Sete News
Medtech CEO Shares Lessons From FIH Implantable Glucose Monitor Trial - Clinical Leader
GlucoTrack Releases Investor Presentation on April 29 - TipRanks
GlucoTrack Inc (NASDAQ:GCTK) stock crossing the finish line today - uspostnews.com
Can GlucoTrack Inc Bounce Back? 52-Week Performance and Analyst Predictions - investchronicle.com
Now Is The Time To Build A Position In GlucoTrack Inc (NASDAQ:GCTK) - Marketing Sentinel
Glucotrack Reports Full Year 2024 Financial Results and Recent Corporate Highlights - ADVFN
It makes sense and dollars to buy GlucoTrack Inc (GCTK) stock - Sete News
Pre-market Movers: OPTN, WINT, AKBA, GCTK... - RTTNews
GlucoTrack Joins EU Bionic Pancreas Initiative - TipRanks
Glucotrack to Participate in FORGETDIABETES, a Prominent European Research Initiative to Develop a Bionic Pancreas - The Manila Times
Major Breakthrough: Glucotrack Selected for EU's Revolutionary Bionic Pancreas Project - Stock Titan
Glucotrack to bring CBGM to bionic pancreas initiative in Europe - Drug Delivery Business
Investing in GlucoTrack Inc (GCTK) might be an excellent idea, but the stock is currently overvalued/undervalued - uspostnews.com
GCTK stock plunges to 52-week low of $0.15 amid market turmoil By Investing.com - Investing.com South Africa
GCTK stock plunges to 52-week low of $0.15 amid market turmoil - Investing.com India
Glucotrack faces Nasdaq delisting over share price rule - Investing.com Australia
Finanzdaten der Glucotrack Inc-Aktie (GCTK)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.31%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):